Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103

Cytotherapy

Volumn 13, Issue 5, 2011, Pages 618-628

  Moreno Bost, Amberly ^a   Szmania, Susann ^a   Stone, Katie ^a   Garg, Tarun ^a   Hoerring, Antje ^b   Szymonifka, Jackie ^b   Shaughnessy Jr , John ^a   Barlogie, Bart ^a   Grant Prentice, H ^c   Van Rhee, Frits ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c CELGENE CORPORATION   (United States)

Author keywords

5 azacitidine; cancer testis antigen; demethylation; epigenetics; histone deactylase inhibitor; hypomethylation; MAGE A3; MGCD0103; multiple myeloma

Indexed keywords

AZACITIDINE; CHROMIUM 51; GAMMA INTERFERON; HISTONE DEACETYLASE INHIBITOR; MELANOMA ANTIGEN 3; MOCETINOSTAT; RNA;

ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CELL KILLING; CELL SPECIFICITY; CHROMIUM 51 RELEASE; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIGENETICS; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERFERON PRODUCTION; MOLECULAR RECOGNITION; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RELAPSE; WESTERN BLOTTING;

EID: 79954455826     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2010.529893     Document Type: Article

References (56)

1. Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, et al. A validated gene expression model of highrisk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109: 2276-84. (Pubitemid 46425864)
2. Vansteenkiste J, Zielinski M, Dahabre J, Linder A, Malinowski W, Jassem J, et al. Multi-center, double blind, randomized, placebo-controlled phase II study to assess the efficacy of recombinant MAGE-A3 vaccine as adjuvant therapy in stage IB/II MAGE-A3 positive, completely resected, non-small cell lung cancer (NSCLC). J Clin Oncol. 2006;24:7019.
3. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005;23:2346-57. (Pubitemid 46218728)
4. Pellat-Deceunynck C, Mellerin MP, Labarriere N, Jego G, Moreau-Aubry A, Harousseau JL, et al. The cancer germ-line genes MAGE-1, MAGE-3 and PRAME are commonly expressed by human myeloma cells. Eur J Immunol. 2000; 30:803-9. (Pubitemid 30216252)
5. van Baren N, Brasseur F, Godelaine D, Hames G, Ferrant A, Lehmann F, et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood. 1999;94: 1156-64. (Pubitemid 29380395)
6. Jungbluth AA, Ely S, DiLiberto M, Niesvizky R, Williamson B, Frosina D, et al. The cancer-testis antigens CT7 (MAGEC1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood. 2005;106:167-74. (Pubitemid 40967189)
7. van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P, et al. NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood. 2005;105:3939-44. (Pubitemid 40656140)
8. Condomines M, Hose D, Raynaud P, Hundemer M, De Vos J, Baudard M, et al. Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J Immunol. 2007;178:3307-15. (Pubitemid 46333216)
9. Andrade VC, Vettore AL, Felix RS, Almeida MS, Carvalho F, Oliveira JS, et al. Prognostic impact of cancer/testis antigen expression in advanced stage multiple myeloma patients. Cancer Immun. 2008;8:2.
10. Atanackovic D, Luetkens T, Hildebrandt Y, Arfsten J, Bartels K, Horn C, et al. Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma. Clin Cancer Res. 2009;15:1343-52.
11. De Smet C, Lurquin C, Lethe B, Martelange V, Boon T. DNA methylation is the primary silencing mechanism for a set of germ line-and tumor-specific genes with a CpG-rich promoter. Mole Cell Biol. 1999;19:7327-35. (Pubitemid 29493396)
12. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol. 2004;22:4632-42. (Pubitemid 41185132)
13. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer. 2004;4:988-93.
14. Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res. 2005;11:8055-62. (Pubitemid 41698748)
15. Wischnewski F, Pantel K, Schwarzenbach H. Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. Mol Cancer Res MCR. 2006;4:339-49. (Pubitemid 43837335)
16. Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, San Jose-Eneriz E, et al. Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia. Haematologica. 2007;92:153-62.
17. Jungbluth AA, Chen YT, Stockert E, Busam KJ, Kolb D, Iversen K, et al. Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer. 2001;92:856-60. (Pubitemid 32467376)
18. Jungbluth AA, Busam KJ, Kolb D, Iversen K, Coplan K, Chen YT, et al. Expression of MAGE-antigens in normal tissues and cancer. Int J Cancer. 2000;85:460-5. (Pubitemid 30075121)
19. dos Santos NR, Torensma R, de Vries TJ, Schreurs MW, de Bruijn DR, Kater-Baats E, et al. Heterogeneous expression of the SSX cancer/testis antigens in human melanoma lesions and cell lines. Cancer Res. 2000;60:1654-62. (Pubitemid 30183438)
20. Sigalotti L, Fratta E, Coral S, Tanzarella S, Danielli R, Colizzi F, et al. Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2′-deoxycytidine. Cancer Res. 2004;64:9167-71. (Pubitemid 39665532)
21. C oral S, Sigalotti L, Colizzi F, Spessotto A, Nardi G, Cortini E, et al. Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications. J Cell Physiol. 2006;207: 58-66.
22. Dubovsky JA, McNeel DG. Inducible expression of a prostate cancer-testis antigen, SSX-2, following treatment with a DNA methylation inhibitor. Prostate. 2007;67:1781-90. (Pubitemid 350228730)
23. Guo ZS, Hong JA, Irvine KR, Chen GA, Spiess PJ, Liu Y, et al. De novo induction of a cancer/testis antigen by 5-aza-2′-deoxycytidine augments adoptive immunotherapy in a murine tumor model [see Comment]. Cancer Res. 2006;66: 1105-13. (Pubitemid 43165979)
24. Honda T, Tamura G, Waki T, Kawata S, Terashima M, Nishizuka S, et al. Demethylation of MAGE promoters during gastric cancer progression. Br J Cancer. 2004;90:838-43. (Pubitemid 38406595)
25. Natsume A, Wakabayashi T, Tsujimura K, Shimato S, Ito M, Kuzushima K, et al. The DNA demethylating agent 5-aza-2′-deoxycytidine activates NY-ESO-1 antigenicity in orthotopic human glioma. Int J Cancer. 2008;122:2542-53. (Pubitemid 351590488)
26. Wang Z, Zhang J, Zhang Y, Lim SH. SPAN-Xb expression in myeloma cells is dependent on promoter hypomethylation and can be upregulated pharmacologically. Int J Cancer. 2006;118:1436-44.
27. Goodyear OC, Agathanggelou A, Ryan G, Novitsky-Basso I, Stankovic T, Moss P, et al. The epigenetic therapies azacitidine and sodium valproate augment immune responses to the MAGE cancer testis antigen in acute myeloid leukemia and myeloma. ASH Annual Meeting Abstracts. 2009;114:823-4.
28. Issa J-PJ, Kantarjian HM. Targeting DNA methylation. Clin Cancer Res. 2009;15:3938-46.
29. Villar-Garea A, Esteller M. Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer. 2004;112:171-8. (Pubitemid 39244355)
30. Acharya MR, Sparreboom A, Venitz J, Figg WD. Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol. 2005;68:917-32. (Pubitemid 41345783)
31. Szmania S, Gnjatic S, Tricot G, Stone K, Zhan F, Moreno A, et al. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma. J Immunother. 2007;30: 847-54. (Pubitemid 350295364)
32. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108:2020-8. (Pubitemid 44395016)
33. Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined signifi-cance, and normal bone marrow plasma cells. Blood. 2002;99: 1745-57. (Pubitemid 34533050)
34. Shaughnessy J, Haessler J, Zeldis J, Huang Y, Zhan F, Sawyer J, et al. An update on the role of thalidomide (THAL) in total therapy 2 (TT2) for newly diagnosed patients with multiple myeloma (MM): analysis of subgroups defined by standard prognostic factors (SPF) and gene expression profiling (GEP) derived subgroups. Blood. 2006;108:968a.
35. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006; 354:1021-30. (Pubitemid 43357806)
36. Barlogie B, Anaissie E, van Rhee F, Haessler J, Hollmig K, Pineda-Roman M, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007;138:176-85. (Pubitemid 46978271)
37. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25:402-8. (Pubitemid 34164012)
38. Gupta S, Zhan F, Lin P, Droogenbroeck J, Batchu R, Nollet F, et al. NY-ESO-1 and MAGE-A3 are highly expressed in myeloma patients with abnormal cytogenetics and/or relapse. Hematol J. 2003;4:S267-8.
39. Goodyear O, Piper K, Khan N, Starczynski J, Mahendra P, Pratt G, et al. CD8- T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden. Blood. 2005;106:4217-24.
40. Atanackovic D, Arfsen J, Cao Y, Gnjatic S, Schneiders F, Bartels K, et al. Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood. 2007;109:1103-12. (Pubitemid 46220657)
41. Cho H, Ely S, Austin W, Niesvizky R, Pearse R, Coleman M, et al. Differential expression of type I MAGE in new and relapsed multiple myeloma: evidence for association with proliferation and progression of disease. Blood. 2006;108:970a.
42. Kasuga C, Nakahara Y, Ueda S, Hawkins C, Taylor MD, Smith CA, et al. Expression of MAGE and GAGE genes in medulloblastoma and modulation of resistance to chemotherapy. Laboratory investigation. J Neurosurg Pediatrics. 2008;1:305-13. (Pubitemid 351534716)
43. Barker PA, Salehi A. The MAGE proteins: emerging roles in cell cycle progression, apoptosis, and neurogenetic disease. J Neurosci Res. 2002;67:705-12. (Pubitemid 34226281)
44. Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, Pierotti MA, et al. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci USA. 2006;103:11160-5. (Pubitemid 44156489)
45. Duan Z, Duan Y, Lamendola DE, Yusuf RZ, Naeem R, Penson RT, et al. Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res. 2003;9:2778-85. (Pubitemid 36842124)
46. Yang B, O'H errin S, Wu J, Reagan-Shaw S, Ma Y, Nihal M, et al. Select cancer testes antigens of the MAGE-A, -B, and -C families are expressed in mast cell lines and promote cell viability in vitro and in vivo. J Invest Dermatol. 2007;127: 267-75. (Pubitemid 46106901)
47. Yang B, O'H errin SM, Wu J, Reagan-Shaw S, Ma Y, Bhat KM, et al. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res. 2007;67: 9954-62. (Pubitemid 47621245)
48. Atanackovic D, Hildebrandt Y, Jadczak A, Cao Y, Luetkens T, Meyer S, et al. Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells. Haematologica. 2010;95:785-93.
49. Atanackovic D, Altorki NK, Cao Y, Ritter E, Ferrara CA, Ritter G, et al. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci USA. 2008;105:1650-5. (Pubitemid 351346569)
50. Gupta S, Pei L, Droogenbroeck J, Szmania S, Yaccoby S, Batchu RB, et al. Intra-and intertumoral variation in the expression of cancer testis antigens, MAGE-3 and NY-ESO-1 in multiple myeloma. Blood. 2002;100:603a.
51. Jungbluth AA, Stockert E, Chen YT, Kolb D, Iversen K, Coplan K, et al. Monoclonal antibody MA454 reveals a heterogeneous expression pattern of MAGE-1 antigen in formalin-fixed paraffin embedded lung tumours. Br J Cancer. 2000;83:493-7. (Pubitemid 30487863)
52. Akcakanat A, Kanda T, Tanabe T, Komukai S, Yajima K, Nakagawa S, et al. Heterogeneous expression of GAGE, NY-ESO-1, MAGE-A and SSX proteins in esophageal cancer: implications for immunotherapy. Int J Cancer. 2006;118:123-8. (Pubitemid 41681588)
53. Dhodapkar MV, Osman K, Teruya-Feldstein J, Filippa D, Hedvat CV, Iversen K, et al. Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun. 2003;3:9.
54. Kufer P, Zippelius A, Lutterbuse R, Mecklenburg I, Enzmann T, Montag A, et al. Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease. Cancer Res. 2002; 62:251-61. (Pubitemid 34074012)
55. Serrano A, Tanzarella S, Lionello I, Mendez R, Traversari C, Ruiz-Cabello F, et al. Expression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2′- deoxycytidine treatment. Int J Cancer. 2001;94:243-51. (Pubitemid 32911420)
56. Hirano N, Butler MO, Xia Z, Berezovskaya A, Murray AP, Ansen S, et al. Efficient presentation of naturally processed HLA class I peptides by artificial antigen-presenting cells for the generation of effective antitumor responses. Clin Cancer Res. 2006;12:2967-75. (Pubitemid 43837340)